Literature DB >> 7090422

Body residue and metabolism of adriamycin and daunorubicin in control and phenobarbital-pretreated mice.

W Bolanowska, T Gessner.   

Abstract

1. Metabolism of adriamycin (ADR) and daunorubicin (DR) was investigated in DBA/2Ha mice after i.p. injection and compared with that in phenobarbital-pretreated animals. At 24 h after drug administration 83% of ADR and 67% of DR derived fluorescence were recovered from cadavers and excreta. Destruction of anthracyclines in excreta to non-fluorescent materials could be partly responsible for the low recoveries. 2. ADR was metabolized to a limited extent in mice. At 24 h 70% dose was detected as the unchanged drug and only 13% as its deoxyaglycones. 3. DR was metabolized more extensively. At 24 h 29% of the dose was as the unchanged drug, while 32% was present as daunorubicinol (DROL) and 16% as aglycones. Phenobarbital did not significantly affect these parameters. 4. In phenobarbital-pretreated mice there was a marked increase in the amount of ADR or DR aglycones in the liver, and a decrease in the levels of unchanged ADR or DR.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7090422     DOI: 10.3109/00498258209046786

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  5 in total

Review 1.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

2.  A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.

Authors:  W Bolanowska; T Gessner; H Preisler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Metabolism of epidoxorubicin in animals: absence of glucuronidation.

Authors:  P A Maessen; K B Mross; H M Pinedo; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Hepatic metabolism of doxorubicin in mice and rats.

Authors:  P Vrignaud; D Londos-Gagliardi; J Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

5.  Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4'-O-methyldoxorubicin in tumor-bearing mice.

Authors:  F Formelli; R Carsana; C Pollini
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.